PainReform (NASDAQ:PRFX) Stock Rating Upgraded by Wall Street Zen

PainReform (NASDAQ:PRFX) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

PainReform Stock Performance

Shares of NASDAQ:PRFX opened at $1.00 on Friday. The company has a market capitalization of $870,000.00, a PE ratio of -0.00 and a beta of 1.06. PainReform has a 12-month low of $0.97 and a 12-month high of $17.95. The business’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $2.30.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.